HIV Gag CTL Epitopes and Their Impact on Disease Progression in Thai Patients
Author Information
Author(s): Mori Masahiko, Sriwanthana Busarawan, Wichukchinda Nuanjun, Boonthimat Chetsada, Tsuchiya Naho, Miura Toshiyuki, Pathipvanich Panita, Ariyoshi Koya, Sawanpanyalert Pathom
Primary Institution: Department of Clinical Medicine, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan
Hypothesis
The study investigates the relationship between Gag CTL responses and clinical outcomes in HIV-infected individuals in Thailand.
Conclusion
The breadth of Gag CTL responses is associated with lower HIV viral loads and delayed initiation of antiretroviral therapy.
Supporting Evidence
- 81.8% of individuals recognized at least one overlapping peptide.
- A greater breadth of CTL response was associated with higher CD4+ T cell counts.
- Individuals with wider CTL responses were less likely to start antiretroviral therapy.
Takeaway
This study found that people with stronger immune responses to a part of the HIV virus called Gag are better at controlling the virus and delaying the need for treatment.
Methodology
The study used ELISpot assays to evaluate CTL responses to overlapping peptides from the Gag protein in HIV-infected individuals.
Potential Biases
Potential bias due to the reliance on statistical methods for OLP-HLA associations without direct evidence.
Limitations
The study focused only on Gag CTL responses and did not investigate other viral proteins, and the OLP-HLA associations were predicted statistically rather than confirmed experimentally.
Participant Demographics
The cohort consisted of 137 treatment-naïve HIV-1 infected individuals, with a median age of 31 years, including 107 females and 30 males.
Statistical Information
P-Value
p=0.0018
Confidence Interval
95% CI of 0.08–0.64
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website